Here we examine the humoral immune response in a subset of human volunteers enrolled in a phase 1 rVSV-ZEBOV vaccination trial by performing comprehensive single B cell and electron microscopy structure analyses. Four studied vaccinees show polyclonal, yet reproducible and convergent B cell responses with shared sequence characteristics. EBOV-targeting antibodies cross-react with other Ebolavirus species, and detailed epitope mapping revealed overlapping target epitopes with antibodies isolated from EVD survivors. Moreover, in all vaccinees, we detected highly potent EBOV-neutralizing antibodies with activities comparable or superior to the monoclonal antibodies currently used in clinical trials. These include antibodies combining the IGHV3-15/IGLV1-40 immunoglobulin gene segments that were identified in all investigated individuals. Our findings will help to evaluate and direct current and future vaccination strategies and offer opportunities for novel EVD therapies. . From all participants, serum, EDTA blood and/or leukapheresis samples were collected and PBMCs were purified by density gradient centrifugation using HistoPaque and stored in FBS containing 10% DMSO (all Merck) at −150 °C. Serum and plasma samples were stored at −80 °C. All enrolled subjects provided written informed consent before participation in the study and all aspects of study conduct were in accordance with Good Clinical Practice. Sera of Ebola virus survivors were collected in the context of the project EVIDENT (Ebola Virus Disease: Correlates of Protection, Determinants of Outcome and Clinical Management) after obtaining informed consent and provided to use as control samples for anti-EBOV IgG titer and neutralizing activity. PBMCs and serum samples from the individuals studied are limited and can only be provided in limited quantities on request.
bola viruses can cause severe infections in humans, leading to unpredictable epidemics with mortality rates of up to 90% 1 . The devastating outbreak in West Africa in 2013-2016 caused >11,000 confirmed deaths 2 . The severe and ongoing outbreak in the Democratic Republic of the Congo (DRC) highlights the significant impact of Ebola virus disease (EVD) and the critical need for efficacious countermeasures 3, 4 .
Different Ebolavirus species can cause symptomatic infection in humans. These include Sudan ebolavirus (SUDV), Bundibugyo ebolavirus (BDBV) and Zaire ebolavirus (EBOV) [5] [6] [7] , with the latter accounting for the current outbreak in the DRC 1, 8 . Studies in animal models have demonstrated that neutralizing antibodies can prevent infection and are effective for post-exposure prophylaxis [9] [10] [11] [12] [13] [14] [15] [16] [17] . Therefore, monoclonal antibodies have been evaluated in clinical trials and administered to patients suffering from EVD [18] [19] [20] [21] [22] . For example, a combination of three antibodies obtained from immunized mice (REGN-EB3) 9 has been tested in a phase I clinical trial 21 . Moreover, the neutralizing antibody mAb114 that was isolated from an EVD survivor 23 has been tested in a clinical trial and demonstrated a preferential pharmacokinetic and safety profile 20 . Until recently, efficacy data in humans were mostly limited to the ZMapp cocktail, which comprises three human-mouse chimeric antibodies (13C6, C2G4 and C4G7). During the 2013-2016 epidemic, ZMapp was tested in EVD patients and reduced fatality rates from 37% to 22% 22 . More promising results have been reported for REGN-EB3 and mAb114, which were administered to EVD patients in a multicenter, randomized controlled clinical trial. In an interim analysis from 499 participants, lethal outcome was markedly reduced from 67% to 29% and 34% with REGN-EB3 and mAb114, respectively 24 .
In addition to passive immunotherapy, several vaccine candidates have been developed [25] [26] [27] [28] . Among them, the recombinant vesicular stomatitis virus (VSV)-based vector carrying the EBOV glycoprotein (rVSV-ZEBOV) is the most advanced vaccine and has been administered to more than 180,000 individuals 24, 27, 29 . rVSV-ZEBOV has been demonstrated to be protective against lethal EBOV challenges in rodents and non-human primates (NHPs) 13, 30, 31 . Moreover, the results of two ring vaccination trials estimate vaccine efficiency to be 97%, and no fatal EVD cases occurred 10 days post vaccination 27, 32 . As a vaccine candidate with available efficacy data, rVSV-ZEBOV has been designated as the lead candidate for administration in current and future EVD outbreaks 33, 34 . However, despite its broad application, a detailed understanding of the rVSV-ZEBOV immune response is still limited and no single-cell analysis has been performed to elucidate the molecular composition of the induced antibody response. Therefore, we set out to investigate the humoral immune response to rVSV-ZEBOV immunization on a molecular level.
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Results
Deciphering the rVSV-ZEBOV-specific B cell response. To analyze the human B cell response to rVSV-ZEBOV vaccination, we collected serum and peripheral blood mononuclear cell (PBMC) samples from six healthy individuals at 18.5 to 26 months after vaccination (Fig. 1a ). The age of participants ranged from 26 to 55 years ( Supplementary Table 1 ) and subjects were vaccinated with 3 × 10 5 (EV01, EV02, EV04) or 3 × 10 6 (EV03, EV05, EV06) plaqueforming units (p.f.u.) of rVSV-ZEBOV (single intramuscular injection). Sera of all participants bound to EBOV glycoprotein (GP) in ELISAs, but with a significantly (P = 0.0013) lower activity than serum samples of EVD survivors (Fig. 1b ). Less to almost no reactivity was detected against GPs from representative viruses of other Ebolavirus species (BDBV and SUDV) and Marburg virus (MARV; Extended Data Fig. 1 ).
To analyze the rVSV-ZEBOV-induced antibody response on a molecular level, we cloned and produced the EBOV GP ectodomain (Δ651-676), introduced a trimerization domain (GCN4 23 ) and tags for purification and labeling (His-and Avi-Tag), and conjugated the resulting protein to a fluorescence marker (the entire construct is referred to as EBOV GP lacking the transmembrane domain ((EBOV GPΔTM), Fig. 1c ). To determine whether EBOV GPΔTM identifies EBOV GP-specific antibodies on cell surfaces, six GP-specific antibodies that have been reported before were cloned into surface expression vectors and expressed on HEK293T cells as a surrogate for GP-specific B cells ( Fig. 1d ). Antibodies recognized different GP epitopes including a discontinuous epitope of base and internal fusion loop (IFL; mAb100). Others bridged GP1 and GP2 (KZ52), bound the GP1 core (mAb114), the GP2 stalk (ADI-15758, ADI-15999) or the glycan cap (ADI-16037). HEK293T cells carrying each of the GP-specific antibodies could be detected by FACS analysis after staining with EBOV GPΔTM (Fig. 1e ). We conclude that EBOV GPΔTM is able to identify anti-EBOV GPΔTM antibodies that recognize various epitopes when expressed on cells and is therefore a suitable protein to isolate EBOV GP-specific B cells and to study the total anti-EBOV GP B cell response in humans.
In six rVSV-ZEBOV-vaccinated subjects, FACS analysis revealed between 0.29% and 0.67% EBOV GPΔTM-reactive IgG + B cells ( Fig. 2a and Extended Data Fig. 2a,b ). Four subjects vaccinated with either 3 × 10 5 (EV01, EV04) or 3 × 10 6 p.f.u. (EV03, EV05) rVSV-ZEBOV were selected for in-depth single B cell and Ig sequence analysis. To this end, we applied nested PCR protocols using highly effective primer sets (Kreer et al., submitted). After quality checks, 1,507 Ig heavy-(V H ) and 261 light-chain variable (V κ/λ ) regions of individual B cells were closely evaluated. Analysis of V H regions revealed clonal origins for 33-46% of sequences ( Fig. 2b ). Among these sequences, we detected a polyclonal response in all subjects, identifying 49, 42, 51 and 45 individual B cell clones for EV01, EV03, EV04 and EV05, respectively ( Fig. 2c and Supplementary Articles NaTuRE MEDICINE chain (IgL) V gene families was comparable among all vaccinees (Fig. 2d ), and the mean germline identity ranged from 90.6% to 94.2% for heavy and 93.9% to 95.9% for light chains ( Fig. 2e ). In addition, only minor differences were detected for the average CDR3 length in amino acids (aa) of IgH (13-15 aa) and IgL (10-11 aa; Fig. 2e ) among vaccinees. Notably, very similar results were observed in an individual (EV07) that received 2 × 10 7 p.f.u. (Extended Data Fig. 3a -e) and when using an alternative bait lacking the TM and mucin-like domain (MLD) (EBOV Makona GPΔTMΔMLD) (Extended Data Fig. 4a,b ). We conclude that rVSV-ZEBOV elicits a polyclonal B cell response that shows similar characteristics among vaccinees, including V gene distribution, CDR3 lengths and levels of somatic hypermutation (SHM). Finally, we compared the EBOV GPΔTM-specific response to the overall B cell repertoire of the same donors (EV01, EV03, EV04 and EV05). To this end, we performed unbiased next generation sequencing (NGS) analyses on heavy chains of the memory B cell compartment of the vaccinees (Extended Data Fig. 2c ). Differences of CDRH3 lengths and SHM between GP-reactive B cells (blue) and the donor-matched B cell memory compartment (gray) were small, with differences ranging from 0.8 to 1.3 aa for the mean CDRH3 lengths and −0.9 to 1.0% for mean V gene germline identity ( Fig. 2f ). However, a striking increase in frequency was detected for the variable gene segment IGHV3-15 ( Fig. 2g ). Indeed, while IGHV3-15 was detected with an average frequency of 1.3% in the memory B cell compartment, we detected a significant 5.4-, 6.4-, 4.8-and 9.9-fold increase for EV01, EV03, EV04 and EV05, respectively. Therefore, we conclude that, while CDRH3 lengths and SHM values are similar between the total memory B cell repertoire and the EBOV GP-specific population, there is a significant increase of IGHV3-15 expressing B cells in the EBOV GP-specific population.
rVSV-ZEBOV induces a convergent B cell response with shared sequence characteristics.
To further investigate the level of convergence in the rVSV-ZEBOV-induced B cell response, we compared heavy chain sequences with the same V H gene among the four individuals studied. By applying a cutoff for the CDRH3 identity of at least 75%, we identified 14 groups that comprised sequences from two or more distinct vaccinees ( Fig. 3a and Supplementary Table 3 ). Within these groups, identical or chemically related heavy and light chain CDR3s across different donors were found ( Fig. 3a ). Of note, we observed antibodies with the same characteristics after vaccination with 2 × 10 7 p.f.u. (Extended Data Fig. 3f ). Quantification of CDRH3 similarities among antibodies within groups that share CDRH3 characteristics revealed a high degree of homology ranging from 74.8% to 95.0% average sequence concordance within groups (Fig. 3b ). Additionally, when integrating a set of sequences obtained from EVD survivors 14 , shared characteristics could also be identified between vaccinees and EVD survivors (Extended Data Fig. 5a,b ). Additionally, we plotted the normalized Levenshtein distances of CDRH3 amino acids (x axis, Fig. 3c ) and the variable regions (y axis, Fig. 3c ) of EBOV GP-specific antibodies. Shared groups are displayed by colored antibodies and cluster in the lower left part of the diagram. Of note, when performing the same analysis on HIV-1 envelope-reactive antibodies, no shared antibody groups were identified. Taken together, these data indicate a convergent antibody response within rVSV-ZEBOV-vaccinated donors ( Fig. 3 ) as well as similarities to the specific antibody response upon EBOV infection (Extended Data Fig. 5 ).
rVSV-ZEBOV-induced antibodies are cross-reactive and target a broad spectrum of epitopes. To produce a broad spectrum of EBOV-directed antibodies, we selected sequences from identified B cell clones as well as a limited number of non-clonal (single) antibody sequences. In total, we cloned and produced 143 antibodies, of which 125 represented members of individual B cell clones and 18 were non-clonal antibodies. Of all 143 antibodies, binding against EBOV GPΔTM was detected in 55-74%. Calculated EC 50 values ranged from 0.03 to 14.4 µg ml −1 (Fig. 4a ) and all EBOV GPΔTM-specific antibodies were also reactive to strain Mayinga (Supplementary Table 4 ). In addition, a large fraction (30.4-75.9%) of antibodies were cross-reactive, with an average of 42.5% recognizing GPs of EBOV, BDBV and SUDV ( Fig. 4b and Supplementary  Table 4 ). Interestingly, four antibodies detected MARV with a mean EC 50 of 4.4 µg ml −1 (Fig. 4b ).
Next, we determined the epitopes of reactive antibodies using several EBOV GP constructs (the trimeric GPΔTM and GPΔTMΔMLD, as well as the structurally different and dimeric secreted GP (sGP), Extended Data Fig. 6a ). For EV01, EV03, EV04 and EV05, 28.6, 47.8, 34.5 and 68.8% of antibodies targeted sGP, respectively, and in 6.3-33.3% binding was dependent on the presence of the MLD (Fig. 4c ). Meanwhile, 14.3-66.7% of EBOV GPΔTM-reactive antibodies competed with either mAb100 or KZ52, which were shown to recognize epitopes on the glycan cap and loop structure 23, 35 . To a lower extent (up to 16.7%), antibodies competed with ADI-15758 and ADI-15999, which target the MPER of GP2 14 (Fig. 4d , Extended Data Fig. 6b and Supplementary Table 4 ). To complement epitope mapping, we assessed binding to linear epitopes for all EBOV Makona GPΔTM-reactive mAbs using a peptide library (Extended Data Fig. 7a and Supplementary Tables 4 and 5 ). The library was validated using control antibodies including KZ52, mAb100, mAb114 and ADI-15758 (Extended Data Fig. 7a ). Of all the antibodies, 52 detected at least one linear peptide, confirming and refining epitope information (Supplementary Table 5 ). In summary, 49.4% of EBOV GPΔTM-reactive antibodies interacted with the N-terminal part of GP1 (sGP) and 16.5% with the MLD. In addition, 7% of the antibodies were directed against the GP2 and 12.9% against GP1/GP2 ( Fig. 4e and Supplementary Tables 4 and 5) . Strikingly, the epitope distribution closely overlapped with epitopes of a collection of antibodies recently characterized in a comprehensive study by Saphire and colleagues 36 (Fig. 4e ). This set of antibodies comprised antibodies from human survivors and 
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antibodies from animal models induced by vaccination or viral challenge. Additionally, a separate epitope analysis of cross-reactive antibodies revealed that 47% of detected epitopes were present on sGP (Extended Data Fig. 7b ). Notably, while only a small fraction of the MLD-detecting antibodies (4 of 13) were cross-reactive, nearly all GP2 binders showed cross-reactivity ( Sequences from different donors with at least 75% CDRH3 homology were defined as a shared group (s1-s16) and, if available, clonal members were added to groups. Sequence origins are color-coded orange, violet, green and yellow for EV01, EV03, EV04 and EV05, respectively. Bold black letters indicate identical amino acids, black letters amino acids with similar chemical characteristics and gray letters different amino acids. 'ND' indicates, where genes or CDR3 domains were not defined. Chemical characteristics were defined by grouping amino acids into non-polar, polar, acidic, basic and aromatic amino acids. b, Quantification of homology of CDRH3 sequences by similarity index. The index was determined using BLOSUM (BLOcks SUbstitution Matrix). c, Percent distance of CDRH3 (x axis) and total sequence distance (y axis) of each sequence to the most similar sequence identified in another donor as calculated by Levenshtein distance normalized on the shorter sequence, if applicable. EBOV GP-reactive antibodies are shown in blue and shared EBOV-specific groups with at least 75% CDRH3 homology in other colors. BG505. SOSIP-reactive antibodies from n = 6 HIV-1-infected individuals are labeled as gray dots. See also Extended Data Figs. 3 and 5 and Supplementary Table 3 . Table 4 ). Interestingly, similar epitope distributions were found in antibodies published in refs. 14, 15 (Extended Data Fig. 7c ). These data illustrate that rVSV-ZEBOV induces a reproducible antibody response that is cross-reactive and targets a broad spectrum of epitopes. Moreover, the rVSV-ZEBOV-induced antibody response recapitulates the epitope distribution found in previously identified antibodies, including those from EVD survivors.
rVSV-ZEBOV-induced mAbs demonstrate potent neutralizing activity. To determine the neutralizing activity of rVSV-ZEBOVinduced antibodies, we performed neutralization assays with wild-type EBOV and SUDV. On serum level, full neutralization of EBOV was observed at higher concentrations in vaccinees (average titer of 1:30) compared to EVD survivors (average titer of 1:104; Fig. 4f ). However, we observed that 34.5-65.2% of rVSV-ZEBOVinduced and EBOV GP-specific antibodies displayed EBOVneutralizing activity ( Fig. 4g ), but no cross-neutralization of SUDV (Supplementary Table 4 ). Nearly 70% of antibodies were found to neutralize within the same range (full neutralization at 0.055-2.5 µg ml −1 ) as control antibodies that have been evaluated in clinical trials (mAb114) 20 and/or showed protection in NHPs (mAb100, ADI-15758, ADI-15999, ADI-16037) 10, 14, 23 . Moreover, some antibodies demonstrated exceptional neutralizing activity by fully preventing infection in vitro, even at 0.01 µg ml −1 (3T0331 and 4T0243, Fig. 4h ). Although epitopes of most neutralizing antibodies were mapped to sGP, various other epitopes were also recognized ( Fig. 4i ). Of all neutralizing antibodies, four targeted the MLD, two competed with ADI-15758 and ADI-15999, and six competed with mAb100 and KZ52. The two most potent neutralizers, 3T0331 and 4T0243, were competitors of mAb100 and KZ52, but with a 5-and 12-fold higher activity, respectively (Fig. 4h ,i and Supplementary Table 4 ). These data demonstrate that rVSV-ZEBOV induces a broad spectrum of neutralizing antibodies that target different epitopes and are of high potency.
Recurrent generation of a specific EBOV-neutralizing antibody class. Although various V genes were observed in EBOVneutralizing antibodies, we detected a significant preference for IGHV3-15 in heavy chains and IGLV1-40 in light chains ( Fig. 5a ). Interestingly, among the 21 antibodies carrying IGHV3-15, 17 showed neutralizing activity ranging from 0.44 to 12.5 µg ml −1 and were exclusively paired with IGLV1-40. Cross-competition ELISAs indicate a similar epitope for all IGHV3-15/IGLV1-40 antibodies and all of them competed with mAb114 ( Fig. 5d ). Of note, this antibody class (IGHV3-15/IGLV1-40) was identified in all four individuals studied (Fig. 5b,c) . The remaining four IGHV3-15 antibodies were paired with other light chains and did not show neutralizing activity ( Fig. 5b and Supplementary Tables 2 and 6) . Notably, this combination was also found frequently in the highdose vaccinee EV07 (11 of 18 analyzed IGHV3-15 antibodies; Extended Data Fig. 3g ).
A detailed sequence comparison of IGHV3-15/IGLV1-40 EBOV-neutralizing antibodies revealed that phylogenetic distances among different donors were small and similar to the distances within single donors (Fig. 5c ). Moreover, in all IGHV3-15/ IGLV1-40 sequences, a high degree of overlapping mutations was observed, indicating a strongly directed affinity maturation process upon rVSV-ZEBOV vaccination ( Fig. 5e and Extended Data Fig. 3h ). For example, in IGHV3-15 heavy chains, various positions were consistently mutated. These include mutations rendering the Ser at position 40 to become an Asn or Thr in 88.2% or within the CDRH1 and CDRH2, in which Ser31, Lys59/Thr60 and Thr64/65 were mutated, in over 50%. Likewise, in IGLV1-40 light chains, Ser58 (CDRL2) was replaced in 100% by mostly Asn or Thr. Moreover, within the CDRL3, serines at positions 110 and 112 were mutated to Arg in 82 and 65%, respectively, and the Gly113 was always mutated to Asp (17 of 17 sequences; Fig. 5e ). We conclude that rVSV-ZEBOV can recurrently elicit a class of EBOVneutralizing antibodies that target sGP and utilize the same V H and V λ genes. Moreover, sequence convergence strongly indicates affinity maturation in a reproducible pattern.
Evaluation and structural analysis of neutralizing mAbs 3T0331 and 4m0368. Antibodies 3T0331 and 4m0368 demonstrate strong EBOV-neutralizing activities (full neutralization at 0.01 µg ml −1 for 3T0331 and 0.13 µg ml −1 for 4m0368; Supplementary Table 4 ), comparable or superior to the activity of anti-EBOV GP antibodies currently used for clinical application 20 (Fig. 4h ). To elucidate the mechanisms of neutralization on a molecular level, we formed complexes of EBOV GP (Mayinga) with the antigen binding fragment (Fab) of 3T0331 and 4m0368 and determined near-atomic-resolution structures using single-particle cryo-electron microscopy (cryo-EM). EBOV GP/3T0331 and EBOV GP/4m0368 complexes were resolved to 3.1 Å ( Fig. 6a and Extended Data Fig. 8a -c) and 3.3 Å ( Fig. 6c and Extended Data Fig. 8a -c), respectively. Both structures were modeled by fitting an available crystallographic structure EV05)). Proportion of binding and non-binding mAbs (left) and EC 50 values of binding mAbs (right). b, Percentage of EBOV GPΔTMspecific mAbs with cross-reactivity against GPs from different filoviruses determined by ELISA (n = 21 (EV01), 23 (EV03), 29 (EV04) and 16 (EV05) (left)) and EC 50 values (n = 42 (BDBV), 32 (SUDV) and 4 (MARV) right). Binding criteria were defined as in a. mAbs specific for GPs of EBOV plus one other filovirus are shown in blue colors and mAbs specific for GPs of EBOV plus two or three other filovirus species are shown in light or dark red, respectively. In a and b, means are indicated by lines. c, Percentage of EBOV GPΔTM-specific antibodies reactive to sGP or MLD determined by ELISA using constructs described in Extended Data Fig. 6a . d, Competition ELISA of EBOV GPΔTM-reactive mAbs with target sites not identified in c. Antibodies for competition included KZ52 and mAb100 that target GP1, IFL and heptad repeat 1 (HR1), as well as ADI-15758 and ADI-15999 that target the membrane proximal external region (MPER). e, Summary of epitope distribution determined by ELISA (c,d) and by peptide library screening of antibodies obtained from rVSV-ZEBOV-immunized individuals (right) compared to the target epitope spectrum and abundance in antibodies published in ref. 36 (left; total numbers are shown in the center of each pie). Unknown epitopes (ND) are shown in gray. See also Extended Data Figs. 4-7 and Supplementary  Table 4 . f, Analysis of serum neutralizing activity of EVD survivors (red) and rVSV-ZEBOV-immunized donors (EV, blue). Shown are dilution factors yielding full neutralization of EBOV Mayinga. Colored background areas indicate the mean values. Significance was tested by two-tailed unpaired t-tests (n = 7 (Survivor) and n = 6 (EV) biologically independent samples, P = 0.089). g, Proportions of neutralizing (blue) and non-neutralizing (gray) antibodies from vaccinees (the number of tested antibodies is shown in the center of each pie). h, Antibody concentrations (μg ml −1 ) required to achieve full neutralization. mAbs obtained from rVSV-ZEBOV-immunized subjects (blue; n = 9 (EV01), 14 (EV03), 10 (EV04), 9 (EV05)) compared to published antibodies (green; KZ52, mAb114, mAb100, ADI-15758, ADI-15999 and ADI-16037). The shaded area illustrates the neutralization range of the reference antibodies. Two mAbs 3T0331 (EV03) and 4T0243 (EV04) are situated below the shaded area. Means are indicated by lines. i, Distribution of neutralizing antibodies by epitopes (n = 26 (sGP), 4 (MLD), 2 (ADI-15758-15999), 6 (KZ52/mAb100) and 4 (Others)). Means are indicated for each sample set. Neutralization experiments were performed in quadruplicate. See also Supplementary Table 4 .
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of EBOV GP (PDB 5JQ3 37 ) into electron density maps. The V H V L portion of 3T0331 was derived from a 1.6 Å resolution structure of 3T0331-Fab determined by X-ray crystallography (Supplementary Table 7 ). The V H V L portion of 4m0368 was computationally modeled using ABpredict 38 . In both structures, the interaction surfaces between the mAbs and EBOV GP were resolved to ~3.0 Å or higher (Extended Data Fig. 8a,d,e ).
Based on these structures, we revealed that antibody 3T0331 binds to the side of the trimeric EBOV GP with a binding angle that probably positions its Fc portion closely to the viral membrane ( Fig. 6a ) and with its epitope spanning the N-terminal region of GP2 as well as limited parts of GP1 (Fig. 6b) . The main contacts with the EBOV GP are made by the burial of EBOV-Val505 in a hydrophobic pocket, as well as a series of polar contacts that include salt bridges between EBOV-Glu502 and two arginine residues from the heavy and light chains (Arg101 and Arg91, respectively), a hydrogen bond between heavy chain Asn54 and a main chain carbonyl of EBOV, a salt bridge between EBOV-Asp552 and heavy chain Lys65, and a hydrogen bond between EBOV-Arg54 and light chain Gln27 (Fig. 6b) . 4m0368, on the other hand, binds the side of the trimeric EBOV GP with an angle that may position its Fc portion further away from the membrane (Fig. 6c ). Its epitope is exclusively limited to residues from the GP2 portion as well as a glycan attached to EBOV-Asn563 (Fig. 6d) . A central interaction is formed by the heavy chain Tyr102 that intercalates between the Asn563-linked glycan and EBOV-Leu529 (Fig. 6d ). Additional interactions include the burial of EBOV-Ile527 in a hydrophobic pocket, a hydrogen bond between EBOV-Trp531 and heavy chain His101, a hydrogen bond between EBOV-Gln521 and light chain Tyr92, as well as a close contact salt bridge and a hydrogen bond between EBOV-Glu564 and heavy chains Arg55 and Tyr54, respectively (Fig. 6d) .
The epitope of 3T0331 on EBOV GP partially overlaps with the previously determined epitopes of ZMapp antibodies C4G7 and C2G4 (Fig. 6e) 22, 39, 40 . Notably, 3T0331 does not bind the side chain of Gln508 from EBOV GP2, which comprises an important part of the epitopes for other base-binding mAbs like C2G4 39 . This residue is a known site for escape mutations 41 and hence 3T0331 may tolerate substitutions at this position. Introducing a Q508R mutation, however, abrogated binding of 3T0331 (data not shown), suggesting that this alteration changes the main chain conformation in this region. Of note, the binding of C2G4 requires some conformational changes at the N-terminal part of GP2 (Extended Data Fig. 9b ), as opposed to 3T0331, which recognizes the native conformation (Extended Data Fig. 9c ). Recognizing the native conformation rather than a presumably less stable altered conformation of EBOV GP may be energetically more favored, and may partially explain the higher potency of 3T0331.
Additionally, 3T0331 and 4m0368 are, in contrast to the chimeric antibodies C4G7 and C2G4, entirely of human origin, and the epitope of 4m0368 overlaps with the EBOV GP-specific mAb100 23, 42 . Of note, when we assessed 3T0331 and 4m0368 for pharmacokinetic behavior in vivo as well as determining their autoreactivity in HepG2 cells, both antibodies showed no or only minor reactivity, and the pharmacokinetics were comparable to two control antibodies (HIV-1-specific antibody 3BNC117 and EBOV GP-specific antibody mAb114), which had half-lives of 17 days (3BNC117) and 24.2 days (mAb114), respectively, in clinical trials 20, 43 (Extended Data Fig. 10 ). In summary, these observations indicate that vaccine-elicited humoral immune responses effectively target previously identified vulnerability sites on EBOV GP and can serve as candidates for preventing and treating Ebolavirus infection.
Discussion
The demand for an Ebolavirus vaccine is increasing, and different potential vaccine candidates have been developed 25, 26, 31 . However, EVD vaccine trials aiming to study efficacy are often impeded by the outbreak nature of EVD and infrastructural challenges 3, 18 . Therefore, it is of critical need to gain detailed mechanistic information on the induced antibody response to comprehensively inform on the development of the best possible EBOV vaccine strategies 33, 44 .
Reproducibility is one of the hallmarks of effective vaccines. Among all of the closely examined subjects, we detected a convergent B cell response that displays (1) the presence of shared antibody characteristics, (2) preferences of V genes found in EBOVreactive mAbs and (3) the frequent generation of a V H 3-15/V λ 1-40 EBOV-neutralizing antibody class that showed traits of a recurrent affinity maturation process. Re-occurring antibodies that share the same V genes have occasionally been reported in response to infections with viruses such as HIV-1, Zika and West Nile virus [45] [46] [47] . For EVD, a longitudinal analysis of four survivors revealed a preference for IGHV3-13 in EBOV-neutralizing antibodies 48 . This gene is also utilized by mAb114 23 and by antibodies that were elicited upon DNA/Ad5 encoded EBOV GP immunization of macaques 49 . EBOV GP-neutralizing antibodies utilizing the same V H gene segment (IGHV3-13) were also detected in our analysis and showed shared antibody characteristics among immunized individuals. In addition, Rijal and colleagues recently isolated antibodies from human donors vaccinated with ChAd3-EBO-Z that were found to be neutralizing. Some of these harbored the combination of the IGHV3-15 and IGLV1-40 gene segments 50 , which we detected as a recurrent and EBOV GP-neutralizing antibody class in all vaccines studied.
As several species cause EVD in humans, antibodies that crossreact with additional species are of particular interest. Such crossreactive antibodies have been observed in EVD survivors 14, 15, 51, 52 , and a recent study reported a cocktail of two pan-Ebolavirus antibodies for therapeutic protection of animal models 10 . Although crossreactivity was low in the sera of vaccinees, 30-75% of monoclonal antibodies potently cross-reacted with other Filoviruses. These data show that the rVSV-ZEBOV vaccine induces cross-reactive monoclonal antibodies and that the intensities of serum reactivities to Ebolavirus GPs alone are not always suitable to predict the development of such antibodies. Finally, epitope mapping revealed a broad coverage of epitopes of EBOV GP, which closely resembled antibodies previously isolated from EVD survivors 14, 15, 36 . These results indicate a successful translation of the antigenic profile from natural EBOV infection to the rVSV-ZEBOV vaccine.
EBOV-neutralizing activity has been demonstrated to be a critical factor for antibody-mediated protection 26, 27, 36, 53 . Although little was known about the time of development of neutralizing antibodies, a recent longitudinal analysis of EVD survivors demonstrated a prolonged antibody maturation process and an increase in neutralizing activity, even many months after acute infection 48 . In another study, rVSV-ZEBOV vaccination was documented to induce an early IgM serum response and suggested a predominant role for IgM antibodies for neutralization and potentially for early protection 54 . In all analyzed rVSV-ZEBOV-vaccinated subjects, we discovered highly potent EBOV GP-specific IgG antibodies. The most potent neutralizers are competitors of the MPER-targeting ADI-15758 and ADI-15999 14 , or of the Articles NaTuRE MEDICINE GP1/2-binding antibodies KZ52 35 and mAb100 23 . Antibodies targeting these epitopes have been demonstrated to protect NHPs against Ebolavirus challenges 23 . Besides neutralizing activity, increasing attention has been paid to Fc-mediated effector functions that contribute to protection 9,55-57 . In our study, 51.7% of isolated EBOV-specific antibodies did not neutralize, and further studies CDRL3  FR3  CDRL2  FR2  11  20  44  53  70  80  93  103   0   3   Bits   1   2   IGLV1-40*01   1T0227  1T0455  3T0245  3T0253  3T0265  3T0338  3T0650  3T0673  4T0452  5T0180  5T0202  5T0209  5T0223  5T0278  5T0337   1T0201   5T0451   FR1  CDRH1  CDRH3  FR3  CDRH2  FR2   IGHV3-15   11  20  45  54  64  103  74 83 93 Articles NaTuRE MEDICINE are needed to determine whether and how these rVSV-ZEBOVinduced antibodies may contribute to effective protection from EBOV infection. A lack of humoral response to EVD infection is associated with fatal outcome in humans 58 , supporting the role of antibodies as treatment options against EVD. Today, antibodies are used as monotherapy (mAb114) or cocktails (ZMapp, REGN-EB3) to treat EVD under expanded access protocols and in clinical trials [18] [19] [20] [21] [22] . Structural analyses of the potent neutralizer 3T0331 demonstrated a strong similarity with C4G7 and C2G4, both members of the ZMapp antibody cocktail 22, 41 . Indeed, because of its favorable preclinical characteristics, including the highly potent neutralizing 
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activity, and its fully human origin, 3T0331 is likely to be a promising candidate to use for clinical applications.
Finally, the identification of potent neutralizing rVSV-ZEBOVinduced antibodies demonstrates the great potential to obtain pathogen-directed human antibodies in the absence of infections and without access to convalescent survivors. VSV-based vaccines have been demonstrated to be generally safe and efficacious, and are currently being developed to protect individuals from other viruses, bacteria and parasites 59 . Although vaccine-induced antibodies have been isolated before 50, 60 , our data highlight this opportunity for VSV-based vaccine strategies and therefore underline the potential to retrieve protecting antibodies that are of particular need in complicated outbreak scenarios and to combat emerging infections.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of code and data availability and associated accession codes are available at https://doi.org/10.1038/ s41591-019-0602-4. . Cells were stained for 20 min at 4 °C, and live CD20 + , IgG + and EBOV GP + cells were sorted using a FACSAriaIII (Becton Dickinson) in a single cell manner into 96-well plates. All wells contained 4 µl lysis buffer (0.5× PBS, 0.5 U µl −1 RNAsin (Promega), 0.5 U µl −1 RNaseOUT (Thermo Fisher Scientific) and 10 mM dithiothreitol (Thermo Fisher Scientific)). After sorting, plates were immediately stored at −80 °C until further processing.
Ig heavy/light chain amplification and sequence analysis. The procedure for PCR amplification was performed as previously described 64,65 but with various adjustments. Briefly, random hexamers (Invitrogen), NP-40 and RNAseOUT (Thermo Fisher Scientific) were added to sorted cells in lysis buffer. The reaction was incubated for 1 min at 65 °C and cooled for at least 2 min on ice. Afterwards, 1× Superscript IV RT buffer, 50 U/rxn SuperScript IV reverse transcriptase, dNTPs, dithiothreitol, RNAseOUT (all Thermo Fisher Scientific) and RNasin (Promega) were added and incubated 15 min at room temperature, 10 min at 50 °C and 10 min at 80 °C. cDNA was used to amplify light and heavy chains using PlatinumTaq HotStart polymerase (Thermo Fisher Scientific) according to the manufacturer's protocol with 6% KB extender and 4 µl cDNA template. Amplification was achieved by sequential semi-nested PCRs using optimized and newly developed primer sets (Kreer et al., submitted) . The results of the PCRs were analyzed by gel electrophoresis and products of correct sizes were subjected to Sanger sequencing. Sequencing chromatograms were filtered for a mean Phred score of 28 and a minimal length of 240 nt. Remaining sequences were annotated with IgBLAST 66 and trimmed to extract only the variable region from FWR1 to the end of the J gene. Base calls within the variable region with a Phred score below 16 were masked and sequences with more than 15 masked nucleotides, stop codons or frameshifts were excluded from further analyses. To identify clonally related sequences within a single subject, we grouped all productive heavy chain sequences of that particular subject by identical V H genes, determined the pairwise Levenshtein distance for their CDRH3s, and assigned an individual clone number to sequence groups that share the same V H gene and have a minimal CDRH3 identity of 75% (with respect to the shortest CDRH3). A total of 100 rounds of input sequence randomization and clonal assignment were performed, and the result with the lowest number of remaining unassigned (non-clonal) sequences was selected for downstream analyses. All clones were cross-validated by the investigators, also taking into account shared mutations. Sequences were denoted as 'shared sequences' across vaccinees if two heavy chains from two different donors had the same V H gene and at least 75% CDRH3 identity (as determined by the Levenshtein distance divided by the length of the shorter CDR3Hs). All members from an intra-donor clone were assigned to a 'shared sequence pool' if the heavy chain of at least one clonal member was identified as a shared sequence. For the identification of the closest sequence pairs between different donors, pairwise Levenshtein distances were calculated for sequences with identical V H genes from different donors and normalized by the shorter V H gene length. CDRH3 distances for the most similar pairs were determined the same way and in the case of two matches with the same overall V H gene similarity, preference was given to the pair with the most similar CDRH3s.
Cloning and production of EBOV GP-specific mAbs. Selected antibody sequences were cloned into mAb expression vectors by sequence-and ligationindependent cloning (SLIC) as previously described 65 . Briefly, amplicons for cloning were produced by PCR amplification using Q5 High Fidelity polymerase (NEB) by standard PCR protocols and previously described primers 64 . PCR products were purified (GeneJET Gel Extraction and DNA Cleanup Micro Kit, Macherey Nagel), cloned into expression vectors by SLIC reaction using T4 DNA polymerase (NEB) and transduced into Escherichia coli DH5α. In total, 4-8 colonies were evaluated by PCR and gel electrophoresis, and forwarded to Sanger sequencing. Plasmids with correct antibody sequences were amplified by midi preparation (Macherey Nagel kit) according to the manufacturer's protocol and stored at 4 °C (short term) or −20 °C.
Heavy and light chain-encoding plasmids were co-transfected into HEK293E cells with PEI reagent as described above. Cultures were harvested after seven days, cell-free supernatants were filtered (0.45 µm filter; Nalgene, Thermo Fisher Scientific) and then incubated with Protein G sepharose (Merck) at 4 °C overnight. Beads were transferred to columns, washed three times with PBS and antibodies were eluted with 0.1 M Glycine (pH 3). Subsequently, the pH of the eluate was neutralized with 1 M Tris-HCl (pH 8). Buffer was exchanged to PBS as described above (in 'Expression and purification of Ebolavirus GPs').
ELISA analysis to determine antibody binding activity to GPs. ELISAs were conducted in high binding 96-well ELISA plates (Corning). Plates were coated with 2.5 µg ml −1 GPs at 4 °C overnight, washed three times with PBST (PBS, 0.05% Tween-20) and blocked with PBST/2% BSA (Carl Roth) for 60 min at room temperature. mAbs were tested at four-or six-fold dilutions (1:3 or 1:5) with starting concentrations of 10 µg ml −1 . After incubation for 90 min at room temperature, plates were washed three times and incubated with horseradish peroxidase (HRP)conjugated goat anti-human IgG antibody (Jackson ImmunoResearch, 1:2,500 in PBST/2% BSA) for 60 min at RT. Reaction was started with 2,2′-azino-bis(3ethyl-benzothiazoline-6-sulfonic acid) solution (ABTS, Thermo Fisher Scientific) and the absorbance (optical density (OD) at 415-695 nm) was measured with an absorbance reader (Tecan) after fixed incubation times. For analysis, time points with overlapping standards curves were selected and ODs as well as EC 50 were determined. Antibodies were considered GP-reactive if the OD was above 0.2 at a mAb concentration of 10 µg ml −1 and the EC 50 did not exceed 15 µg ml −1 .
EBOV GPΔTM peptide library. EBOV GPΔTM strain Makona was divided into 80 peptides with a length of 18 aa and an overlap of 10 aa. Peptides were synthesized by Thermo Fisher Scientific PEPOTEC IMMUNO (project Unbiased B cell repertoire analyses. B cell receptor repertoire sequence data were generated by an unbiased template-switch-based NGS approach. In brief, 250,000 CD20 + /IgG + B cells were sorted for each individual and RNA was isolated with the RNeasy Micro Kit (Qiagen) using a QiaCube (Qiagen) instrument. cDNA was generated by template-switch reverse transcription according to the SMARTer RACE 5′/3′ manual (Takara/Clonetech) with a self-designed template-switch oligo that included an 18 nt unique molecular identifier (UMI). Heavy chain variable regions were amplified with an IgG-specific nested PCR and amplicons were used for library preparation and illumina MiSeq 2 × 300 bp sequencing.
NGS sequence processing. Raw read pre-processing was performed with an inhouse pipeline primarily based on self-written Python scripts, IgBLAST 66 , Clustal Omega 67 and the pRESTO toolkit 68 . Raw reads were filtered for a mean Phred quality score of 25 and a mean read length of 250 bp. UMIs were extracted and IgBLAST was used to pre-annotate reads. Each read pair was annotated with its top V gene call, its UMI and an additional 18 nt molecular identifier (MID) starting 12 nt after the framework region (FWR) 3. UMIs were grouped and sequences (referred to as 'collisions') were removed if they differed from the most abundant V gene call or had more than 1 nt difference to the remaining reads in their UMI group. We assumed that reads with the same V gene/MID and an UMI edit distance of 1 nt are more likely to represent reverse transcription (RT), PCR or sequencing errors within the UMI than real different molecules. To rescue those erroneous UMIs, we re-grouped colliding reads and remaining single UMI reads by their MID and re-defined MID groups as the same UMI group, if they shared the same V gene and their UMI had no more than 1 nt difference. UMI groups were aligned with Clustal Omega and then collapsed to build consensus reads. To this end, we weighted each base call by its quality (1 − error probability) and generated sums for different base calls over each position to account for both total abundance and the corresponding quality. The base with the highest sum was taken as the consensus base. Paired consensus reads were assembled to one sequence using the pRESTOs AssemblePairs module with a minimal overlap of 6 nt. The number of UMI counts per consensus read was plotted against the total number of sequences. This gives a bimodal distribution with a large peak for single reads (UMI found only once) and a broader peak at roughly 20-100 UMIs per consensus read, representing the average oversequencing per molecule. We set an individual cutoff for the minimal UMI number at the intersection of both distributions for each sample (EV01 = 14, EV03 = 8, EV04 = 6, EV05 = 10) to get rid of artificial diversity that mainly comes from PCR and sequencing errors within the UMIs. Assembled full-length sequences were annotated with IgBLAST and only productive sequences with full sequence annotation were kept for downstream analysis. V gene usage, CDR3 length and V gene germline identity distributions were determined from all final sequences without further collapsing.
Cloning, expression and purification of EBOV GP ectodomain for structural studies. The ectodomain of EBOV GP (PDB 5JQB_A) was chemically synthesized (Genscript) to eliminate the mucin-like region and to include a C-terminal trimerization domain of T4 fibritin (foldon) followed by a His-tag as previously reported 37 . The truncated EBOV GP gene was subcloned into a modified pHLsec expression vector (BD Biosynthesis) and transfected using 40 kDa polyethylenimine (PEI-MAX, Polysciences) at 1 mg of plasmid DNA per 1 l of HEK293F cells (Invitrogen). To inhibit the formation of complex glycosylation, the mannosidase inhibitor kifunensine (Cayman Chemical) was added to a final concentration of 5 μM. Media were collected after 6 days and supplemented with 0.02% (wt/ vol) sodium azide and PMSF. Media were collected and buffer exchanged to TBS (20 mM Tris-HCl pH 8.0, 150 mM sodium chloride) using a tangential flow filtration system (Merck Millipore). Protein was captured using a HiTrap IMAC FF Ni 2+ (GE Healthcare) affinity column followed by size exclusion chromatography (SEC) purification with a Superdex 200 10/300 column (GE Healthcare).
Cloning and purification of anti-EBOV GP Fabs for crystallography. Anti-EBOV GP IgG clones 3T0331 and 4m0368 were expressed in HEK293F suspension cells (Invitrogen) by co-transfecting the heavy and light chains encoding vectors. Transfections were carried out using PEI-MAX (Polysciences). Media were collected after 6 days of incubation and IgGs were captured using protein-A affinity chromatography (Merck). IgGs were digested using Papain (Merck) with an enzyme and protein ratio of ~1:20. Digestion proceeded for 60 min at 37 °C in a buffer containing 20 mM cystein-HCl (Merck) and 10 mM EDTA titered to pH 7.0. Fabs were separated from Fc fragments by collecting the flowthrough fraction from a protein-A column, followed by SEC on a Superdex 75 10/300 column. Fabs were mixed with EBOV GP ectodomain at a molar ratio of 1:2, and the complex was isolated by SEC on a Superdex 200 10/300.
Crystallization, data collection and structure determination of Fab 3T0331.
A mosquito crystallization robot (TTP labs) was used to set 60, 120 and 180 nl sitting drops of Fab 3T0331 (11 mg ml −1 ) with a 120 nl reservoir of commercially available crystallization screens. Crystallization hit for the Fab was identified using a PEGRx HT kit (Hampton). Crystals were obtained in 0.15 M lithium sulfate monohydrate, 0.1 M citric acid pH 3.5, 18% PEG 6000 at 20 °C. Crystals were briefly soaked in mother liquor solution supplemented with 25% ethylene glycol for cryo preservation before flash cooling in liquid nitrogen. X-ray diffraction data were collected at the European Synchrotron Radiation Facility (ESRF) at beamline ID23-2 using a Pilatus3 2M detector. Diffraction data were collected to a resolution of 1.56 Å using X-ray radiation at a wavelength of 0.87313 Å at 100 K. Images were indexed, integrated using Xia2 69 , and scaled using Aimless 70 . A molecular replacement solution was found using Phaser 71 with a single Fab in the asymmetric unit, and the model was built and refined in an iterative manner using Coot 72 and Phenix refine 73 . 98.14% of the residues in the refined model occupied favored Ramachandran space and an additional 1.86% of the residues were in allowed Ramachandran space.
Cryo-EM image acquisition, data processing and model building.
Complexes of EBOV GP/Fabs (0.4 mg ml −1 ) were applied to glow-discharged C-flat 2/1-3Cu-50 holey carbon grids (EMS) and plunge frozen in liquid ethane, using a ThermoFisher Vitrobot plunger (2.5 s blotting time, 100% humidity). Cryo-EM data were collected on a Titan Krios electron microscope (FEI) operated at 300 kV. Coma-free alignment was performed with AutoCTF (FEI) and the beam size was 2.2 μm. Videos were recorded on a Falcon 3EC direct detector (ThermoFisher) and were collected in super-resolution counting mode at a nominal magnification of ×96,000 corresponding to a physical pixel size of 0.85 Å. The total dose rate was set to one electron per physical pixel per second and the total exposure time was 29.6 s, resulting in an accumulated dose of 40 electrons per Å 2 . Each movie was fractionated into 39 frames of 0.76 s. The nominal defocus range was −0.5 to −2.3 μm. A total of 437 and 723 videos were recorded for EBOV GP/3T0331 and EBOV GP/4m0368, respectively.
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All data processing was conducted using the cryoSPARC V2 suite 74 . Videos were motion-corrected and contrast transfer functions were fitted using CTFFIND4 75 . Templates for auto picking were derived by two-dimensional (2D) classification of manually picked particles. Following template-based autopicking, a total of 109,407 and 123,880 good particles were selected for reconstruction of EBOV GP/3T0331 and EBOV GP/4m0368, respectively, based on iterative reference-free 2D classifications. Initial reference maps were calculated using ab initio reconstruction and high-resolution maps were obtained using non-uniform 3D refinement, while imposing C3 symmetry. Working maps were locally filtered after calculating local resolution estimates.
Models of EBOV GP/3T0331 and EBOV GP/4m0368 were assembled by rigid-body fitting the crystallographic structure of EBOV GP (PDB 5JQ3) 37 into electron density maps using UCSF chimera 76 as well as of the V H V L portions from the crystallographic structure of 3T0331 and from a computationally modeled 4m0368. The latter structure was modeled using the ABpredict tool 38 . Both structures were then refined using the Phenix real-space refinement tool 73 and manually fitted into electron density maps using Coot 72 in an iterative process.
Estimation of antibody pharmacokinetic profiles in vivo. NOD.Cg-Rag1 tm1mom Il2rg tm1Wjl /SzJ mice (The Jackson Laboratory), 22-36 weeks of age, were injected intravenously with 0.5 mg of antibody (200 µl at a concentration of 2.5 mg ml −1 in PBS, tail vein) on day 0. Total human IgG serum concentrations were determined over a period of 14 days by ELISA as described previously 77 . Briefly, high binding ELISA plates (Corning) were coated overnight with goat anti-human IgG (Jackson ImmunoResearch) and blocked with 2% BSA, 1 µM EDTA and 0.1% Tween-20 in PBS for 2 h. Serum and standard samples were incubated for 90 min, followed by HRP-conjugated goat anti-human IgG (Jackson ImmunoResearch) for 90 min. Absorbance at 415 nm was determined (Tecan) after the addition of ABTS (Thermo Fisher). Plates were washed with 0.05% Tween-20 in PBS between each step. The absence of detectable human IgG was confirmed in all mice using pre-infusion serum samples. Mouse experiments were authorized by the State Agency for Nature, Environment and Consumer Protection (LANUV) of North Rhine-Westphalia.
Quantification and statistics. Flow cytometry analysis and quantifications were performed with FlowJo10. EC 50 values, means and standard deviations of serum and antibody reactivities were calculated from technical replicates (n = 2 per sample; serum samples n = 6 for EV, n = 7 for EVD survivor) using GraphPad Prism (version 7). Tests for significance were conducted using GraphPad Prism and R (R Core Team, 2018). Differences in survivor and rVSV-ZEBOV vaccinees (serum response and neutralization) were tested by two-tailed unpaired t-tests. The frequency increase of the 58 different V genes between EBOV GPΔTMspecific B cell sequences and the IgG repertoire ( Fig. 2g ) was analyzed by normalizing each data set (EBOV GPΔTM-specific and IgG repertoire) on relative frequencies for each of the four vaccinees and computing the differences among relative frequencies. To test the significance for the single V genes, two data sets were generated. Set A included all four differences for the V gene of interest, and set B included 57 differences, one for each other V gene, where the subject was chosen uniformly at random. A one-sided Mann-Whitney U (rank sum) test was applied on the two sets to determine whether set A was stochastically greater than set B. To account for the random sampling in the construction of set B, this setup was repeated 10 3 times and the averaged resulting P values were used with α = 0.05 and Bonferroni correction for multiple testing. The frequency increase of V genes of EBOV-neutralizing antibodies (Fig. 6a ) was tested for significance using a binomial test under the null hypothesis of equal V gene frequency, α = 0.05 and Bonferroni correction. The sequence similarity of CDRH3 was determined by Geneious software using BLOSUM (BLOcks Substitution Matrix) with residue-specific and hydrophilic gap penalties (open gap penalty of 10, extended gap penalty 0.2). The calculations of phylogenetic trees and sequence alignments were done with Geneious (version 10). To compare the heterogeneity of sequences within the same donor with that among different donors, pairwise alignment scores among all sequences were computed by needle (with default parameters) and grouped accordingly. The difference of both distributions of alignment scores was assessed with a Mann-Whitney U test. Sequence logo plots were generated with WebLogo3 78 followed by minor adjustments. Last updated by author(s): Aug 29, 2019 Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.
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Data collection
No data were collected except own data (see also below). Flow cytometry data were gained by FACSAriaIII with BD FACSDiva software. ELISA plates were measured by Tecan's Sunrise absorbance microplate reader and associated software. Microscopic pictures were taken with Leica DMI microscope (fluorescence) and a Titan Krios electron microscope (FEI) operating at 300 kV (cryo-EM). X-ray diffraction data were collected at the European Synchrotron Radiation Facility (ESRF) at beamline ID23-2 using a Pilatus3 2M detector. B cell receptor repertoire sequence data were generated by an unbiased template-switch-based NGS approach (Kreer et al., manuscript in preparation). Raw read pre-processing was performed with an in-house pipeline primarily based on self-written Python scripts, IgBLAST, Clustal Omega, and the pRESTO toolkit. Antibody sequence data were gained by PCR sequencing at GATC or Eurofins genomics.
Data analysis
Antibody sequence analysis: Sequencing chromatograms were filtered for a mean Phred score of 28 and a minimal length of 240 nt. Remaining sequences were annotated with IgBLAST (Ye et al., 2013) and trimmed to extract only the variable region from FWR1 to the end of the J gene. Base calls within the variable region with a Phred score below 16 were masked and sequences with more than 15 masked nucleotides, stop codons, or frameshifts were excluded from further analyses. In order to identify clonally related sequences within a single subject, we grouped all productive heavy chain sequences of that particular subject by identical VH genes, determined the pairwise Levenshtein distance for their CDRH3s, and assigned an individual clone-number to sequence groups that share the same VH gene and have a minimal CDRH3 identity of 75% (with respect to the shortest CDRH3). 100 rounds of input sequence randomization and clonal assignment were performed and the result with the lowest number of remaining unassigned (non-clonal) sequences was selected for downstream analyses.
NGS sequence processing: Raw read pre-processing was performed with an in-house pipeline primarily based on self-written Python scripts, IgBLAST (Ye et al., 2013) , Clustal Omega (Sievers et al., 2011) , and the pRESTO toolkit (Vander Heiden et al., 2014). Raw reads were filtered for a mean Phred quality score of 25 and a mean read length of 250 bp. Unique molecular identifiers (UMIs) were extracted and IgBLAST was used to pre-annotate reads. Each read pair was annotated with its top V gene call, its UMI, and an additional 18 nt molecular identifier (MID) starting 12 nt after the framework region (FWR) 3. UMIs were grouped and sequences (referred to as "collisions") were removed if they differed from the most abundant V gene call or had more than 1 nt difference to the remaining reads in their UMI group. We assumed that reads with the same V gene/MID and an UMI edit distance of 1 nt are more likely to represent RT,
